QPS Announces New Global Clinical Research Operations Leadership

QPS, a leading global contract research organization (CRO), is pleased to announce new clinical research operations leadership. This new clinical leadership will further align the existing global medical affairs, regulatory affairs, data services, and clinical operations units with the existing successful QPS Phase I clinics. The enhanced global capabilities will help QPS satisfy the need for agility, flexibility, and speed in the quickly evolving global drug development community.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620868635/en/

QPS Holdings, LLC corporate headquarters in Delaware Technology Park in Newark, Delaware. This location is also the QPS Bioanalysis Laboratory Center of Excellence for small and large molecule drug development. (Photo: Business Wire)

“This addition of Mr. Derek Grimes to the QPS Global Leadership Team will enhance our ability to collaborate across business units to offer comprehensive custom-built clinical development programs to better address a future dominated by Biologics and Advanced Therapy programs and a demand for accelerated clinical trials,” said Benjamin Chien, Chairman, President and CEO of QPS.

Mr. Derek Grimes, QPS Executive Vice President and Global Head of Clinical Research is a distinguished executive with 26 years of leadership experience in healthcare and clinical research across both academic and private institutions. He has played a pivotal role in developing complex healthcare and clinical research organizations and has been the operational lead on several hundred clinical research programs for academic and industry-based organizations. Grimes’ extensive experience and contributions to the field have made him a respected leader in clinical research and healthcare management. Most recently, Grimes served as the Senior Vice President of Clinical Operations at Frontage Laboratories, where he led the operations for the Clinical Services Division.

“I am excited to join the team and look forward to getting started. There is huge potential in the QPS full-service global CRO offering and enhanced alignment of leadership across the units will benefit our clients tremendously,” says Grimes.

In 2022, QPS announced a full transformation to a globally structured organization leading to seamless delivery of preclinical, bioanalytical, and clinical trial services around the world. At the same time, the organization formalized its medical affairs and regulatory affairs departments and onboarded new senior leaders for those teams. This enhanced structure has benefited our global customers, as our teams now more closely collaborate across all global regions. The addition of Grimes to this organization will further solidify QPS’ ability to serve Biotech and Pharmaceutical clients around the world.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620868635/en/